ImmunoGen (IMGN -0.76%), Seattle Genetics (SGEN 0.06%), Exelixis (EXEL 4.44%), Alnylam Pharmaceuticals (ALNY 1.12%), Momenta Pharmaceuticals (MNTA), and bluebird bio (BLUE -1.54%) are all up at least 10% as of 1:32 p.m. EST following Donald Trump's presidential election win.
Hillary Clinton had taken a tough stance against drug prices, and as it looked more likely that she was going to win, investors factored the potential for new laws that might limit drug pricing and increase competition into their valuations. Now that's she's lost, it's only natural that investors would re-evaluate drugmakers' valuations.
What's interesting is that a few of these companies -- ImmunoGen, Alnylam, and Bluebird -- aren't generating any revenue from drugs on the market, so it'll be awhile before any new laws would affect them. And Momenta makes generic drugs, which you'd think would benefit from hypothetical new laws designed to spur competition. Exelixis and Seattle Genetics have drugs on the market, so the move higher makes a little more sense.
While biotech investors can revel in the moves today -- and if they're lucky, the party will continue for a little while longer -- eventually further gains will be determined by how productive the biotechs are in selling their current drugs and developing new ones.